No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US ETFDetailed Quotes
DIVG INVESCO S&P 500 HIGH DIVIDEND GROWERS ETF
- 31.220
- +0.149+0.48%
Trading Mar 11 09:36 ET
0.000High0.000Low
0.000High0.000Low3Volume31.000Open31.071Pre Close0.00Turnover0.00%Turnover Ratio--P/E (Static)100.00KShares32.58052wk High--P/B3.12MFloat Cap25.92052wk Low1.32Dividend TTM100.00KShs Float32.580Historical High4.24%Div YieldTTM0.00%Amplitude24.463Historical Low0.000Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday
The Analyst Verdict: Gilead Sciences In The Eyes Of 14 Experts
Express News | Cell therapy company 2seventy bio surged over 76% in pre-market trading after reaching an acquisition agreement with Bristol-Myers Squibb, which will acquire the company at a price of $5 per share.
Gilead Sciences Analyst Ratings
Buffett's "skills remain sharp" as Berkshire outperformed the Magnificent 7 this year! How to find a safe haven for funds?
On March 10, Monday, the "Magnificent 7" and other Technology giants all saw declines of at least 2%, with Tesla dropping over 15%, the largest drop since September 2020, nearly halving its stock price this year. In contrast, Berkshire Hathaway, led by Buffett, has seen its stock price rise over 9% this year.